Birdwatch Note
2024-10-09 02:17:44 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
次世代mRNAワクチン・コスタイベは安全なワクチンです https://www.mixonline.jp/tabid55.html?artid=77254 ワクチン薬害が発生しているという客観的な証拠は存在しないことに留意しましょう。 なお日本看護倫理学会は日本医学会連合に参加していません。つまり医学の専門家が集まる研究団体ではありません。 https://www.jmsf.or.jp/accession/index.html 日本看護倫理学会は看護倫理の専門家が集まる研究団体です。ワクチンやウイルスの専門家集団ではありません。 https://www.jnea.net/about/outline/
Written by 169D2EB0CE4FAED029CE904443460D0C85651746DF09A0E57E6B11180B88C5D0
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1843819228719395253
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1843838225124856070
- noteId - 1843838225124856070
- participantId -
- noteAuthorParticipantId - 169D2EB0CE4FAED029CE904443460D0C85651746DF09A0E57E6B11180B88C5D0 Participant Details
- createdAtMillis - 1728440264385
- tweetId - 1843819228719395253
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 次世代mRNAワクチン・コスタイベは安全なワクチンです https://www.mixonline.jp/tabid55.html?artid=77254 ワクチン薬害が発生しているという客観的な証拠は存在しないことに留意しましょう。 なお日本看護倫理学会は日本医学会連合に参加していません。つまり医学の専門家が集まる研究団体ではありません。 https://www.jmsf.or.jp/accession/index.html 日本看護倫理学会は看護倫理の専門家が集まる研究団体です。ワクチンやウイルスの専門家集団ではありません。 https://www.jnea.net/about/outline/
Note Ratings
rated at | rated by | |
2024-10-22 05:39:49 -0500 | Rating Details | |
2024-10-09 21:59:19 -0500 | Rating Details | |
2024-10-09 17:06:27 -0500 | Rating Details | |
2024-10-09 03:28:39 -0500 | Rating Details | |
2024-10-09 00:39:58 -0500 | Rating Details | |
2024-10-09 00:28:19 -0500 | Rating Details | |
2024-10-08 23:44:29 -0500 | Rating Details | |
2024-10-08 23:21:50 -0500 | Rating Details | |
2024-10-08 23:18:43 -0500 | Rating Details | |
2024-10-08 23:02:33 -0500 | Rating Details | |
2024-10-08 23:01:06 -0500 | Rating Details | |
2024-10-08 22:53:18 -0500 | Rating Details | |
2024-10-08 22:47:09 -0500 | Rating Details | |
2024-10-08 22:44:04 -0500 | Rating Details | |
2024-10-08 22:36:10 -0500 | Rating Details | |
2024-10-08 22:32:43 -0500 | Rating Details | |
2024-10-08 22:31:14 -0500 | Rating Details | |
2024-10-08 22:25:13 -0500 | Rating Details | |
2024-10-08 22:18:01 -0500 | Rating Details | |
2024-10-08 22:17:26 -0500 | Rating Details | |
2024-10-08 22:08:55 -0500 | Rating Details | |
2024-10-08 22:02:58 -0500 | Rating Details | |
2024-10-08 21:57:46 -0500 | Rating Details | |
2024-10-08 21:56:36 -0500 | Rating Details | |
2024-10-08 21:52:01 -0500 | Rating Details | |
2024-10-08 21:43:42 -0500 | Rating Details | |
2024-10-08 21:33:34 -0500 | Rating Details | |
2024-10-09 02:53:01 -0500 | Rating Details | |
2024-10-09 02:18:59 -0500 | Rating Details | |
2024-10-09 01:19:20 -0500 | Rating Details | |
2024-10-09 01:13:54 -0500 | Rating Details | |
2024-10-08 23:37:52 -0500 | Rating Details | |
2024-10-08 23:06:08 -0500 | Rating Details | |
2024-10-08 22:49:35 -0500 | Rating Details | |
2024-10-08 22:46:21 -0500 | Rating Details | |
2024-10-08 22:25:31 -0500 | Rating Details | |
2024-10-08 22:22:31 -0500 | Rating Details | |
2024-10-08 22:12:41 -0500 | Rating Details | |
2024-10-08 22:10:19 -0500 | Rating Details | |
2024-10-08 22:06:05 -0500 | Rating Details | |
2024-10-08 22:05:12 -0500 | Rating Details | |
2024-10-08 22:02:14 -0500 | Rating Details | |
2024-10-08 21:46:28 -0500 | Rating Details | |
2024-10-08 21:42:38 -0500 | Rating Details |